Why the study?
Hyperlipidemia is the main risk factor for atherosclerosis-related diseases including ischemic stroke, necessitating optimized lipid-lowering therapy in post-stroke patients.
How should lipid-lowering therapy be optimized to achieve target LDL-C levels in patients after ischemic stroke?
How should lipid-lowering therapy be optimized to achieve target LDL-C levels in patients after ischemic stroke?
Provides an expert consensus algorithm for sequential lipid-lowering therapy (statins, ezetimibe, PCSK9 inhibitors) to achieve target LDL-C in post-ischemic stroke patients.
Answers are grounded in this paper and cite their sources.
Algorithm guides sequential lipid-lowering post-ischemic stroke; leaves open outcome impact without prospective validation.
Hyperlipidemia is the main risk factor for diseases caused by atherosclerosis including ischemic stroke. This publication provides practical recommendations and an algorithm for prescribing lipid-lowering therapy to post-ischemic stroke patients. The algorithm presents the steps for sequential administration of statins, ezetimibe, and PCSK9 inhibitors to achieve target levels of low-density lipoprotein cholesterol.
No takes yet. Share an insight, caveat, or question.
Shamalov et al. (2020) conducted a review in Ischemic stroke. Lipid-lowering therapy (statins, ezetimibe, PCSK9 inhibitors) was evaluated. An expert consensus algorithm provides practical recommendations for the sequential administration of statins, ezetimibe, and PCSK9 inhibitors to achieve target LDL cholesterol after ischemic stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: